Brief: Cartesian Therapeutics Announces Strategic Licensing Agreement With Westgene Biopharma To Accelerate The Development Of In Vivo Car-T Platform In Autoimmune Diseases
BRIEF-Cartesian Therapeutics Announces Strategic Licensing Agreement With Westgene Biopharma To Accelerate The Development Of In Vivo Car-T Platform In Autoimmune Diseases June 9 (Reuters) - Cartesian Therapeutics Inc RNAC.O:
CARTESIAN THERAPEUTICS ANNOUNCES STRATEGIC LICENSING AGREEMENT WITH WESTGENE BIOPHARMA TO ACCELERATE THE DEVELOPMENT OF IN VIVO CAR-T PLATFORM IN AUTOIMMUNE DISEASES
CARTESIAN THERAPEUTICS ANNOUNCES STRATEGIC LICENSING AGREEMENT WITH WESTGENE BIOPHARMA TO ACCELERATE THE DEVELOPMENT OF IN VIVO CAR-T PLATFORM IN AUTOIMMUNE DISEASES
CARTESIAN THERAPEUTICS - CLINICAL TRIAL WITH DESCARTES-8 MRNA AND WESTGENE LNP IN MG TO START 2H 2026
CARTESIAN THERAPEUTICS - WESTGENE TO RECEIVE UPFRONT AND POTENTIAL MILESTONE PAYMENTS UNDER AGREEMENT
CARTESIAN THERAPEUTICS - CLINICAL STUDY TO INITIATE 2H 2026 WITH IN-HUMAN DATA EXPECTED 1H 2027
Source text: ID:nGNXbnwjyX
Further company coverage: RNAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview